Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Kenneth R. Chapman,Kathryn Cogger,Erin Arthurs,Callahan LaForty,Shane Golden,Bradley Millson,Koyo Usuba,Christopher Licskai
DOI: https://doi.org/10.1186/s13223-023-00863-7
2024-02-06
Allergy Asthma & Clinical Immunology
Abstract:Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with severe asthma. The impact of mepolizumab in a real-world, publicly funded healthcare setting is unknown. The objective of this study was to describe the demographics and clinical characteristics of real-world patients receiving mepolizumab, and to compare asthma-related outcomes and associated asthma-related costs before and during mepolizumab use.
immunology,allergy
What problem does this paper attempt to address?